Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
Di Giorgio C, Morretta E, Lupia A, Bellini R, Massa C, Urbani G, Bordoni M, Marchianò S, Lachi G, Rapacciuolo P, Finamore C, Sepe V, Chiara Monti M, Moraca F, Natalizi N, Graziosi L, Distrutti E, Biagioli M, Catalanotti B, Donini A, Zampella A, Fiorucci S. Di Giorgio C, et al. Among authors: sepe v. Biochem Pharmacol. 2024 May;223:116134. doi: 10.1016/j.bcp.2024.116134. Epub 2024 Mar 15. Biochem Pharmacol. 2024. PMID: 38494064 Free article.
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.
Di Giorgio C, Bellini R, Lupia A, Massa C, Bordoni M, Marchianò S, Rosselli R, Sepe V, Rapacciuolo P, Moraca F, Morretta E, Ricci P, Urbani G, Monti MC, Biagioli M, Distrutti E, Catalanotti B, Zampella A, Fiorucci S. Di Giorgio C, et al. Among authors: sepe v. Front Oncol. 2023 Mar 14;13:1140730. doi: 10.3389/fonc.2023.1140730. eCollection 2023. Front Oncol. 2023. PMID: 36998446 Free PMC article.
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Di Giorgio C, Bellini R, Lupia A, Massa C, Urbani G, Bordoni M, Marchianò S, Rosselli R, De Gregorio R, Rapacciuolo P, Sepe V, Morretta E, Monti MC, Moraca F, Cari L, Ullah KRS, Natalizi N, Graziosi L, Distrutti E, Biagioli M, Catalanotti B, Donini A, Zampella A, Fiorucci S. Di Giorgio C, et al. Among authors: sepe v. Cell Oncol (Dordr). 2024 Apr;47(2):695-710. doi: 10.1007/s13402-023-00893-8. Epub 2023 Nov 9. Cell Oncol (Dordr). 2024. PMID: 37945798 Free PMC article.
Bile acids and bile acid activated receptors in the treatment of Covid-19.
Fiorucci S, Urbani G, Biagioli M, Sepe V, Distrutti E, Zampella A. Fiorucci S, et al. Among authors: sepe v. Biochem Pharmacol. 2023 Dec 9:115983. doi: 10.1016/j.bcp.2023.115983. Online ahead of print. Biochem Pharmacol. 2023. PMID: 38081371 Free article. Review.
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease.
Fiorucci S, Rapacciuolo P, Fiorillo B, Roselli R, Marchianò S, Di Giorgio C, Bordoni M, Bellini R, Cassiano C, Conflitti P, Catalanotti B, Limongelli V, Sepe V, Biagioli M, Zampella A. Fiorucci S, et al. Among authors: sepe v. Front Pharmacol. 2022 Apr 25;13:858137. doi: 10.3389/fphar.2022.858137. eCollection 2022. Front Pharmacol. 2022. PMID: 35559268 Free PMC article.
Combinatorial targeting of G-protein-coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug-induced liver injury.
Biagioli M, Marchianò S, di Giorgio C, Roselli R, Bordoni M, Bellini R, Fiorillo B, Sepe V, Catalanotti B, Cassiano C, Monti MC, Distrutti E, Zampella A, Fiorucci S. Biagioli M, et al. Among authors: sepe v. Hepatology. 2023 Jul 1;78(1):26-44. doi: 10.1002/hep.32787. Epub 2022 Oct 12. Hepatology. 2023. PMID: 36107019
145 results